Logo
x

Search category

Subscribe Now

MAA

Incyte Reports EMA's Validation of MAA for Ruxolitinib Cream to Treat Vitiligo

Incyte Reports EMA's Validation of MAA for Ruxolitinib Cream to Treat Vitiligo

  • October 29, 2021
ADC Reports EMA's Validation of MAA for Zynlonta to Treat R/R Diffuse Large B-Cell Lymphoma

ADC Reports EMA's Validation of MAA for Zynlonta to Treat R/R Diffuse Large B-Cell Lymphoma

  • October 29, 2021
Incyte Reports EMA's Validation of MAA for Ruxolitinib Cream to Treat Vitiligo

Incyte Reports EMA's Validation of MAA for Ruxolitinib Cream to Treat Vitiligo

  • October 29, 2021
ADC Reports EMA's Validation of MAA for Zynlonta to Treat R/R Diffuse Large B-Cell Lymphoma

ADC Reports EMA's Validation of MAA for Zynlonta to Treat R/R Diffuse Large B-Cell Lymphoma

  • October 29, 2021
BMS Reports EMA's Validation of MAA for Relatlimab and Nivolumab as 1L Treatment for Unresectable or Metastatic Melanoma

BMS Reports EMA's Validation of MAA for Relatlimab and Nivolumab as 1L Treatment for Unresectable or Metastatic Melanoma

  • October 1, 2021
BMS Reports EMA's Validation of MAA for Relatlimab and Nivolumab as 1L Treatment for Unresectable or Metastatic Melanoma

BMS Reports EMA's Validation of MAA for Relatlimab and Nivolumab as 1L Treatment for Unresectable or Metastatic Melanoma

  • October 1, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.